In a trial milestone, participants in the third patient group of the ASPIRO Phase 1/2a study (NCT06344026) are now receiving the commercial formulation of ANPD001, Aspen Neuroscience’s cell therapy candidate […] The post First trial group gets commercial formulation of Parkinson’s therapy appeared first on Parkinson's News Today.
